LENZ Therapeutics, Inc.
LENZ
$29.94
-$0.09-0.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.37M | 28.81M | 24.91M | 21.27M | 16.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.45M | 58.61M | 68.37M | 75.29M | 75.90M |
| Operating Income | -59.45M | -58.61M | -68.37M | -75.29M | -75.90M |
| Income Before Tax | -47.74M | -49.77M | -60.99M | -69.65M | -74.13M |
| Income Tax Expenses | 1.00K | 1.00K | -179.00K | -179.00K | -179.00K |
| Earnings from Continuing Operations | -47.74 | -49.77 | -60.81 | -69.47 | -73.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.74M | -49.77M | -60.81M | -69.47M | -73.95M |
| EBIT | -59.45M | -58.61M | -68.37M | -75.29M | -75.90M |
| EBITDA | -59.36M | -58.55M | -68.34M | -75.26M | -75.88M |
| EPS Basic | -1.77 | -4.77 | -16.35 | -25.59 | -32.72 |
| Normalized Basic EPS | -1.10 | -2.98 | -10.27 | -16.05 | -20.51 |
| EPS Diluted | -1.77 | -4.77 | -16.35 | -25.59 | -32.72 |
| Normalized Diluted EPS | -1.10 | -2.98 | -10.27 | -16.05 | -20.51 |
| Average Basic Shares Outstanding | 107.80M | 84.99M | 59.47M | 34.26M | 10.60M |
| Average Diluted Shares Outstanding | 107.80M | 84.99M | 59.47M | 34.26M | 10.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |